title: Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. IV. Differential activation of human Th1 and Th2 lymphocytes and influence of the atopic status on lymphoma development.
abstract: Intraperitoneal transfer of PBMC from EBV+ donors into SCID mice leads to high human Ig levels in mouse serum and B cell lymphoproliferative disease. As these events depend on the activation of coinjected human T cells, we addressed the behavior of the Th1 and Th2 subsets in this model. Production of IFN-gamma, but not of Th2 cytokines such as IL-4, was detected in culture supernatants of PBMC stimulated in vitro with mouse splenocytes. Moreover, anti-CD3 stimulation of the human cells recovered from mice brought about IFN-gamma, but not IL-4, synthesis; on the other hand, PCR and in situ hybridization analysis of ex vivo-recovered cells disclosed the presence of mRNA for both cytokines following in vitro restimulation, thus suggesting posttranscriptional regulation of IL-4 gene expression. When SCID mice were inoculated with PBMC from atopic donors, whose Th1/Th2 profile displays an imbalance toward Th2 cells, tumor development rates were lower, and tumor latency was higher, compared with those in mice injected with PBMC from normal donors. Isotypic analysis of human Ig in mouse serum showed the exclusive presence of IFN-gamma-driven IgG subclasses; in addition, human IgE were low or undetectable in most cases. These findings indicate that following transfer into SCID mice, human Th1 lymphocytes undergo preferential activation, whereas Th2 function is down-regulated. Th1 lymphocytes probably are a major component in promoting EBV+ B cell expansion and tumor development; the individual Th1/Th2 profile could in part account for the as yet unexplained donor variability in tumor generation in this experimental model.
authors.affiliation: Department of Oncology and Surgical Sciences, Interuniversity Center for Research on Cancer, University of Padua, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Coppola
authors.forename: A
authors.initials: A
authors.lastname: Veronesi
authors.forename: S
authors.initials: S
authors.lastname: Indraccolo
authors.forename: F
authors.initials: F
authors.lastname: Calderazzo
authors.forename: M
authors.initials: M
authors.lastname: Mion
authors.forename: S
authors.initials: S
authors.lastname: Minuzzo
authors.forename: G
authors.initials: G
authors.lastname: Esposito
authors.forename: D
authors.initials: D
authors.lastname: Mauro
authors.forename: B
authors.initials: B
authors.lastname: Silvestri
authors.forename: P
authors.initials: P
authors.lastname: Gallo
authors.forename: P
authors.initials: P
authors.lastname: Falagiani
authors.forename: A
authors.initials: A
authors.lastname: Amadori
authors.forename: L
authors.initials: L
authors.lastname: Chieco-Bianchi
mesh_terms: D000328:Adult; D000818:Animals; D015478:Antigens, Heterophile / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000096:biosynthesis / Q000235:genetics; D015847:Interleukin-4 / Q000096:biosynthesis / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000378:metabolism / Q000637:transplantation*; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology*; D008223:Lymphoma / Q000209:etiology* / Q000235:genetics / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D012333:RNA, Messenger / Q000032:analysis; D018417:Th1 Cells / Q000276:immunology* / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism
chemical_list: D015478:Antigens, Heterophile; D007074:Immunoglobulin G; D012333:RNA, Messenger; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma